The αvβ6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma

Journal of Hepatology

Volumn 52, Issue 3, 2010, Pages 362-369

  Patsenker, E ^a   Wilkens, L ^a   Banz, V ^b   Osterreicher C H ^c   Weimann, R ^a   Eisele, S ^a   Keogh, A ^b   Stroka, D ^b   Zimmermann, A ^a   Stickel, F ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cholangiocyte; Cytokeratin; Hepatocellular carcinoma; Integrin; Metastasis

Indexed keywords

ALPHAVBETA6 INTEGRIN; BIOLOGICAL MARKER; MESSENGER RNA; CYTOKERATIN 20; CYTOKERATIN 7; INTEGRIN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BETA CHAIN; BILE DUCT CARCINOMA; CANCER CELL CULTURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; EVALUATION; FEMALE; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CANCER; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS CARCINOMA; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; UPREGULATION; BILE DUCT TUMOR; INTRAHEPATIC BILE DUCT; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; SCLEROSING CHOLANGITIS; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; INTEGRINS; KERATIN-20; KERATIN-7; LIVER NEOPLASMS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 77249113715     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.12.006     Document Type: Article

References (41)

1. Khan S.A., Thomas H.C., Davidson B.R., and Taylor-Robinson S.D. Cholangiocarcinoma. Lancet 366 (2005) 1303-1314
2. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 3 (2006) 33-42
3. Malhi H., and Gores G.J. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 45 (2006) 856-867
4. Khan S.A., Davidson B.R., Goldin R., Pereira S.P., Rosenberg W.M., Taylor-Robinson S.D., et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51 Suppl. 6 (2002) VI1-VI9
5. Brumm C., Schulze C., Charels K., Morohoshi T., and Kloppel G. The significance of alpha-fetoprotein and other tumour markers in differential immunocytochemistry of primary liver tumours. Histopathology 14 (1989) 503-513
6. Ganjei P., Nadji M., Albores-Saavedra J., and Morales A.R. Histologic markers in primary and metastatic tumors of the liver. Cancer 62 (1988) 1994-1998
7. Jovanovic R., Jagirdar J., Thung S.N., and Paronetto F. Blood-group-related antigen Lewis(x) and Lewis(y) in the differential diagnosis of cholangiocarcinoma and hepatocellular carcinoma. Arch Pathol Lab Med 113 (1989) 139-142
8. Nakajima T., and Kondo Y. Well-differentiated cholangiocarcinoma: diagnostic significance of morphologic and immunohistochemical parameters. Am J Surg Pathol 13 (1989) 569-573
9. Kakar S., Gown A.M., Goodman Z.D., and Ferrell L.D. Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med 131 (2007) 1648-1654
10. Rullier A., Le Bail B., Fawaz R., Blanc J.F., Saric J., and Bioulac-Sage P. Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. Am J Surg Pathol 24 (2000) 870-876
11. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 110 (2002) 673-687
12. Volpes R., van den Oord J.J., and Desmet V.J. Integrins as differential cell lineage markers of primary liver tumors. Am J Pathol 142 (1993) 1483-1492
13. Mizejewski G.J. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 222 (1999) 124-138
14. Van Waes C. Cell adhesion and regulatory molecules involved in tumor formation, hemostasis, and wound healing. Head Neck 17 (1995) 140-147
15. Eble J.A., and Haier J. Integrins in cancer treatment. Curr Cancer Drug Targets 6 (2006) 89-105
16. Pignatelli M., Cardillo M.R., Hanby A., and Stamp G.W. Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors. Hum Pathol 23 (1992) 1159-1166
17. Patsenker E., Popov Y., Stickel F., Jonczyk A., Goodman S.L., and Schuppan D. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 135 (2008) 660-670
18. Popov Y., Patsenker E., Stickel F., Zaks J., Bhaskar K.R., Niedobitek G., et al. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol 48 (2008) 453-464
19. Breuss J.M., Gallo J., DeLisser H.M., Klimanskaya I.V., Folkesson H.G., Pittet J.F., et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci 108 Pt 6 (1995) 2241-2251
20. Breuss J.M., Gillett N., Lu L., Sheppard D., and Pytela R. Restricted distribution of integrin beta 6 mRNA in primate epithelial tissues. J Histochem Cytochem 41 (1993) 1521-1527
21. Lee J.M., Dedhar S., Kalluri R., and Thompson E.W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172 (2006) 973-981
22. Sipos B., Hahn D., Carceller A., Piulats J., Hedderich J., Kalthoff H., et al. Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology 45 (2004) 226-236
23. Xue H., Atakilit A., Zhu W., Li X., Ramos D.M., and Pytela R. Role of the alpha(v)beta6 integrin in human oral squamous cell carcinoma growth in vivo and in vitro. Biochem Biophys Res Commun 288 (2001) 610-618
24. Regezi J.A., Ramos D.M., Pytela R., Dekker N.P., and Jordan R.C. Tenascin and beta 6 integrin are overexpressed in floor of mouth in situ carcinomas and invasive squamous cell carcinomas. Oral Oncol 38 (2002) 332-336
25. Kawashima A., Tsugawa S., Boku A., Kobayashi M., Minamoto T., Nakanishi I., et al. Expression of alphav integrin family in gastric carcinomas: increased alphavbeta6 is associated with lymph node metastasis. Pathol Res Pract 199 (2003) 57-64
26. Saijyo S., Kudo T., Suzuki M., Katayose Y., Shinoda M., Muto T., et al. Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med 177 (1995) 61-71
27. Maruyama M., Kobayashi N., Westerman K.A., Sakaguchi M., Allain J.E., Totsugawa T., et al. Establishment of a highly differentiated immortalized human cholangiocyte cell line with SV40T and hTERT. Transplantation 77 (2004) 446-451
28. Joplin R. Isolation and culture of biliary epithelial cells. Gut 35 (1994) 875-878
29. Hernandez B.Y., Frierson H.F., Moskaluk C.A., Li Y.J., Clegg L., Cote T.R., et al. CK20 and CK7 protein expression in colorectal cancer: demonstration of the utility of a population-based tissue microarray. Hum Pathol 36 (2005) 275-281
30. -/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol 43 (2005) 1045-1054
31. Patsenker E., Popov Y., Wiesner M., Goodman S.L., and Schuppan D. Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. J Hepatol 46 (2007) 878-887
32. Wu P.C., Fang J.W., Lau V.K., Lai C.L., Lo C.K., and Lau J.Y. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol 149 (1996) 1167-1175
33. Sell S., and Dunsford H.A. Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am J Pathol 134 (1989) 1347-1363
34. Hakkinen L., Koivisto L., Gardner H., Saarialho-Kere U., Carroll J.M., Lakso M., et al. Increased expression of beta6-integrin in skin leads to spontaneous development of chronic wounds. Am J Pathol 164 (2004) 229-242
35. Wang B., Dolinski B.M., Kikuchi N., Leone D.R., Peters M.G., Weinreb P.H., et al. Role of alphavbeta6 integrin in acute biliary fibrosis. Hepatology 46 (2007) 1404-1412
36. Yano Y., Yamamoto J., Kosuge T., Sakamoto Y., Yamasaki S., Shimada K., et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol 33 (2003) 283-287
37. Ng I.O., Shek T.W., Nicholls J., and Ma L.T. Combined hepatocellular-cholangiocarcinoma: a clinicopathological study. J Gastroenterol Hepatol 13 (1998) 34-40
38. Ahmed N., Riley C., Rice G.E., Quinn M.A., and Baker M.S. Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer. J Histochem Cytochem 50 (2002) 1371-1380
39. Bates R.C., Bellovin D.I., Brown C., Maynard E., Wu B., Kawakatsu H., et al. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 115 (2005) 339-347
40. Smythe W.R., LeBel E., Bavaria J.E., Kaiser L.R., and Albelda S.M. Integrin expression in non-small cell carcinoma of the lung. Cancer Metastasis Rev 14 (1995) 229-239
41. Rygiel K.A., Robertson H., Marshall H.L., Pekalski M., Zhao L., Booth T.A., et al. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab Invest 88 (2008) 112-123